Stockscreener 앱 받기
13.35
4.23%
-0.59
전일 마감가:
$13.94
열려 있는:
$13.94
하루 거래량:
2.06M
Relative Volume:
1.30
시가총액:
$789.19M
수익:
$122.29M
순이익/손실:
$122.31M
주가수익비율:
6.1981
EPS:
2.1539
순현금흐름:
$12.00M
1주 성능:
-4.51%
1개월 성능:
-1.11%
6개월 성능:
+57.24%
1년 성능:
+11.06%
1일 변동 폭
$12.96
$13.96
1주일 범위
$12.96
$15.04
52주 변동 폭
$7.16
$15.04
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(888) 958-1253
주소
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
13.35 | 789.19M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | BTIG Research | Buy |
| 2025-07-02 | 개시 | H.C. Wainwright | Buy |
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Is Zevra’s Broad Russell Index Inclusion Reshaping the Investment Case for Zevra Therapeutics (ZVRA)? - Sahm
Zevra Therapeutics (ZVRA) Q4 2024 earnings summary - Quartr
Form 144 ZEVRA THERAPEUTICS For: 8 July By Investing.com - Investing.com India
[144] ZEVRA THERAPEUTICS, INC. SEC Filing - Stock Titan
Zevra Therapeutics (ZVRA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary - Quartr
Zevra Therapeutics (ZVRA) Surges 3.11%: Support and Resistance Levels in FocusStandard Deviation - dars.gov.et
ZVRA News | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Is Zevra Therapeutics (ZVRA) Blending Niche Rare-Disease Focus With Mainstream Index Visibility Effectively? - Sahm
ZVRAZevra Therapeutics Inc Dividends - Finviz
(ZVRA) Risk Channels and Responsive Allocation - Stock Traders Daily
Enterprise value to revenue forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value Benchmark - marketscreener.com
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Value Benchmark Index - marketscreener.com
ZVRA Q1 2026 Earnings: Earnings Per Share Surges Past Estimates with 118% SurpriseNew Analyst Coverage - dars.gov.et
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index - marketscreener.com
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to book forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to sales forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Price to sales forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Enterprise value to EBIT forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Price to earnings forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Enterprise value to EBITDA forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Defensive Index - marketscreener.com
Zevra Therapeutics, Inc. Actuals & Estimates (SWB:1GDA) - TradingView
Zevra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:1GDA) - TradingView
Zevra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ZVRA) - TradingView
Zevra Therapeutics, Inc. Actuals & Estimates (DUS:1GDA) - TradingView
1GDA Forecast — Price Target — Prediction for 2027 - TradingView
Zevra Therapeutics publishes phase 2 3 study on arimoclomol for Niemann-Pick disease type C in infants - Traders Union
ZVRA Forecast — Price Target — Prediction for 2027 - TradingView
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating - Moomoo
H.C. Wainwright reiterates Zevra Therapeutics stock rating on infant study data - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) - Sahm
Zevra Therapeutics chief legal & compliance sells $438,303 in stock By Investing.com - Investing.com South Africa
Form 4 Zevra Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
ZVRA: Zevra Therapeutics Releases Positive Findings on Arimoclom - GuruFocus
Zevra Therapeutics chief legal & compliance sells $438,303 in stock - Investing.com
Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise - Stock Titan
ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
Zevra Therapeutics reports positive MIPLYFFA pediatric data - grafa.com
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Zevra Therapeutics Announces Publication of Positive - GlobeNewswire
(ZVRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Alicia Secor Takes A Bullish Stance, Acquiring $51K Worth Of Zevra Therapeutics Stock Options - Benzinga
Corey M. Watton Seizes Opportunity: Acquires $51K Worth Of Zevra Therapeutics Stock Options - Benzinga
Director at Zevra Therapeutics (ZVRA) granted 30,000 stock options - Stock Titan
Zevra Therapeutics (ZVRA) director awarded 30,000 options at $11.17 strike - Stock Titan
Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant - Stock Titan
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Zevra Therapeutics Inc 주식 (ZVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thompson Rahsaan | Chief Legal & Compliance |
Jun 22 '26 |
Sale |
12.68 |
34,557 |
438,304 |
80,235 |
| Thompson Rahsaan | Chief Legal & Compliance |
May 11 '26 |
Sale |
11.30 |
1,794 |
20,272 |
48,125 |
2.64%
자본화:
|
볼륨(24시간):